Company Legal Name
Latest Valuation
Founded Year
Headquarter
ConcertAI develops an integrated software suite that leverages real-world data and artificial intelligence to optimize oncology research and clinical trials. Founded in 2017 and headquartered in Cambridge, the company addresses critical inefficiencies in cancer drug development by providing pharmaceutical companies, research institutions, and healthcare providers with advanced analytics and data-driven insights. ConcertAI's platform aggregates diverse oncology datasets to accelerate patient recruitment, improve trial design, and enhance treatment outcomes. The company serves a growing market of stakeholders seeking to reduce the time and cost associated with bringing new cancer therapies to market through intelligent data utilization.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





